HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys.

Abstract
The CTLA4-Ig fusion proteins abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) costimulatory ligands and are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplantation, respectively. Abatacept and belatacept preferentially bind CD80, yet CD86 has been implicated as the dominant ligand for CD28-mediated costimulation of T cells. We investigated the immunosuppressive effects of ASP2408, a novel CTLA4-Ig with CD86 selectivity and high potency created by directed evolution methods. Here we evaluated the effect of ASP2408 in vitro using cynomolgus monkey and rat T cell proliferation assays and in vivo using cynomolgus monkey tetanus toxoid (TTx) immunization and a rat rheumatoid arthritis model. ASP2408 was 290-fold and 21-fold more potent in suppressing in vitro monkey T cell proliferation than abatacept and belatacept, respectively. ASP2408 inhibited anti-TTx immunological reactions in cynomolgus monkey at a 10-fold lower dose level than belatacept, through complete CD86 and partial CD80 receptor occupancies, and also suppressed inflammation in the rat collagen-induced arthritis model. Overall, improved immunosuppressive potency of ASP2408 relative to abatacept and belatacept correlated well with improved CD86 binding affinity. These results may support the advantage of preferential enhancement of CD86 binding affinity to inhibit T cell-mediated immune response and improved dosing convenience in humans relative to abatacept or belatacept.
AuthorsShinsuke Oshima, Yasutomo Fujii, Erik E Karrer, Fujiko Takamura, Steven J Chapin, Margaret Neighbors, Sridhar Viswanathan, Bruce H Devens, Yasuyuki Higashi, Hidekazu Mizuhara
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 40 Pg. 310-317 (Nov 2016) ISSN: 1878-1705 [Electronic] Netherlands
PMID27662596 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • B7-1 Antigen
  • B7-2 Antigen
  • Collagen Type II
  • Immunosuppressive Agents
  • Tetanus Toxoid
  • Abatacept
Topics
  • Abatacept (blood, pharmacology, therapeutic use)
  • Animals
  • Arthritis, Experimental (drug therapy, pathology)
  • Arthritis, Rheumatoid (drug therapy, pathology)
  • B7-1 Antigen (immunology)
  • B7-2 Antigen (immunology)
  • Cell Proliferation (drug effects)
  • Collagen Type II (immunology)
  • Female
  • Foot (pathology)
  • Immunosuppressive Agents (blood, pharmacokinetics, pharmacology, therapeutic use)
  • Macaca fascicularis
  • Male
  • Rats
  • T-Lymphocytes (drug effects)
  • Tetanus Toxoid (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: